GlassScriptPhysician profile
Ann K Williams
NPI 1043216732
$4,064.12
in general payments reported to CMS, 2019-2025
25 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $126 · 2021: $521 · 2022: $413 · 2023: $817 · 2024: $1,029 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172 · Gift: $96.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.74 |
| Gift | $96.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,172.01 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Harrow Eye, LLC | $552.20 | 2023-2025 | Vevye, Iheezo, Triesence |
| Alcon Vision LLC | $531.65 | 2019-2025 | Hydrus Microstent |
| Rxsight INC | $279.93 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $249.73 | 2019-2021 | |
| Abbvie INC. | $229.48 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $218.01 | 2023-2025 | Envista Mx60 Iol, Miebo, Lotemax Sm |
| Allergan, INC. | $166.07 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $114.39 | 2024-2025 | Xdemvy |
| Beaver-Visitec International, INC. | $82.34 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $67.51 | 2019-2021 | |
| Dompe US, INC. | $66.38 | 2022-2024 | Oxervate |
| Astellas Pharma US INC | $63.31 | 2024-2025 | Izervay, Veozah |
| Mallinckrodt Hospital Products INC. | $54.25 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $32.54 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $29.63 | 2019 | |
| Thea Pharma INC. | $22.56 | 2023 | Iyuzeh |
| Sight Sciences, INC. | $20.37 | 2021 | |
| Shire North American Group INC | $20.14 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.40 | 2021 | |
| Omeros Corporation | $17.44 | 2019 | |
| Biotissue Holdings INC. | $16.24 | 2025 | |
| Horizon Therapeutics Plc | $14.19 | 2021 | |
| Eyepoint US, INC. | $13.50 | 2019 | |
| Glaukos Corporation | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.